Positive Celltrion Review Bodes Well For Other Biosimilars
This article was originally published in Scrip
Executive Summary
A positive review by FDA scientists may have just put Celltrion Inc.'s CTP13, a version of Janssen Biotech Inc.'s tumor necrosis factor (TNF) blocker Remicade (infliximab), in line to be the next biosimilar to enter the US market, although the product must first get past a panel of experts at a Feb. 9 advisory committee meeting.